Study of the Role of Genetic Modifiers in Hemoglobinopathies
About this study
This study will investigate the role of genetic modifiers in hemoglobinopathies through a large-scale, multi-ethnic genome-wide association study (GWAS).
- Condition
- Sickle Cell Disease, Thalassemia, Beta, Thalassemia Alpha, Hemoglobinopathies
- Tested
- GWAS
- Sponsor
- Cyprus Institute of Neurology and Genetics
Who can join
- Age
- 2 years and older
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 5
- Minimum age: 2 years
- Study condition: Sickle Cell Disease, Thalassemia, Beta, Thalassemia Alpha, Hemoglobinopathies
- Clinical diagnosis of an inherited hemoglobinopathy, including sickle cell disease (SCD), β-thalassemia, and α-thalassemia; all genotypes will be considered.
- Age ≥ 2 years old at the time of the collection of the phenotypic data.
- There will be no limits on study participants in terms of gender, ethnicity, morbidities.
Exclusion 3
- Patients treated with stem cell transplantation or genetic therapy.
- Age \< 2 years old at the time of the collection of the phenotypic data.
- Patient or legal representative for minors unwilling or unable to give consent.
Where
26 sites, 26 recruiting
Lucrecia Paím Maternity
Luanda, Angola
Larnaca General Hospital
Larnaca, Cyprus
Limassol General Hospital
Limassol, Cyprus
Archbishop Makarios III Hospital
Nicosia, Cyprus
Paphos General Hospital
Paphos, Cyprus
Centre Hospitalier Monkole
Kinshasa, Democratic Republic of the Congo
and 20 more sites on ClinicalTrials.gov
Contact
-
Petros Kountouris, PhD
22392623 admin@inherentnetwork.org
Potential match only. Final eligibility is determined by the study team.